Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s FARXIGA (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (CKD) Stages 2-4 and elevated urinary albumin excretion.
FSD Pharma has filed an application with the US Food and Drug Administration (FDA) seeking its approval to launch a phase 2 trial for FSD201 (ultramicronised palmitoylethanolamide, or ultramicronised PEA) in Covid-19 patients.
Treadwell Therapeutics announced the initiation of three expansion cohorts in its ongoing Phase 1 study evaluating CFI-402257, a selective and highly potent oral inhibitor of tyrosine threonine kinase (TTK).
Novartis announced that, at primary analysis, the Phase III ASCEMBL study met its primary endpoint of statistically significant superiority in major molecular response (MMR) rate at 24 weeks for asciminib (ABL001) vs. bosutinib.
AstraZeneca has initiated a phase 1 trial of a monoclonal antibody combination called AZD7442, which is being developed for the prevention and treatment of Covid-19.
Odonate Therapeutics announced positive top-line results from CONTESSA, a Phase 3 study of tesetaxel in patients with metastatic breast cancer (MBC).
Novartis announced today that the Phase III COMBI-i study evaluating the investigational immunotherapy spartalizumab (PDR001), in combination with the targeted therapies Tafinlar (dabrafenib) and Mekinist (trametinib), did not meet its primary endpoint of investigator-assessed progression-free survival.
SAB Biotherapeutics said that it has dosed the first patient in the phase 1b trial of SAB-185 for evaluating its safety and pharmacological activity as a potential treatment for Covid-19.
Continuous monitoring provides a real-time data advantage over batch or non-continuous methods of total organic carbon (TOC) measurement.
Pfizer and BioNTech shared additional Phase 1 safety and immunogenicity data from their ongoing U.S. study of the BNT162 mRNA-based vaccine program against SARS-CoV-2, which has advanced into Phase 2/3 evaluation.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.